Mar 16, 2009 - AVANIR Pharmaceuticals today announced that it has completed targeted enrollment of patients into the STAR trial, a confirmatory Phase III trial of Zenvia™ (dextromethorphan/quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA).
The details can be read here.
No comments:
Post a Comment